MedPath

LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)

Phase 3
Completed
Conditions
Li Fraumeni Syndrome
Interventions
Other: whole body MRI
Registration Number
NCT01464086
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Brief Summary

The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
107
Inclusion Criteria
  • P53 mutation
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intensive follow-upwhole body MRIStandard follow-up plus whole body MRI at inclusion, one and two years
Primary Outcome Measures
NameTimeMethod
cancer incidence3 years

cancer incidence during the first 3 years

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Institut Gustave Roussy

🇫🇷

Villejuif, France

© Copyright 2025. All Rights Reserved by MedPath